VERTEX PHARMACEUTICALS INC | 27,576 Euro | +0,121 +0,44 % | |
| WKN: 882807 ISIN: US92532F1003 Ticker-Symbol: VX1 | Frankfurt | 10.02.12 | 17:30 Uhr |
Branche PharmaAktienmarkt NASDAQ-100NASDAQ Biotech |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 09.02. | Vertex Pharmaceuticals has the Highest Sales Growth in the Biotechnology Industry | 26 | SmarTrend | |
| 07.02. | Uptrend Call Working As Vertex Pharmaceuticals Stock Rises 25.8% | 19 | SmarTrend | |
| 03.02. | Vertex Pharma Down 5% After INCIVEK sales disappoint. | 56 | Benzinga.com | |
| 03.02. | Downgrade Alert for Vertex Pharmaceuticals | 61 | SmarTrend | |
| 03.02. | Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript | 36 | Seeking Alpha | |
| 02.02. | Vertex Pharma Turns To Profit In Q4 On INCIVEK Net Revenues | 107 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc's (VRTX)
GAAP net income for the fourth quarter of 2011 was $158.6 million, or $0.74 per
share, compared to a net loss of... Mehr lesen zu: Vertex Pharma Turns To Profit In Q4 On INCIVEK Net Revenues | ||||
| 02.02. | Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results | 57 | Business Wire | |
| -Successful launch of INCIVEK (telaprevir) for hepatitis C and recent
approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for
continued growth, earnings... Mehr lesen zu: Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results | ||||
| 02.02. | Perception, Opportunity in Volatility - Research & Analysis on Vertex Pharmaceuticals Incorporated and Pfizer Inc. | 40 | MarketWire | |
| HONG KONG -- (Marketwire) -- 02/02/12 -- This morning, www.MarketFoundations.com announced new reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Pfizer Inc. (NYSE: PFE).... Mehr lesen zu: Perception, Opportunity in Volatility - Research & Analysis on Vertex Pharmaceuticals Incorporated and Pfizer Inc. | ||||
| 01.02. | Vertex: Nächster Hoffnungsträger mit Zulassung | 236 | Der Aktionär | |
| Das hat man noch nicht gesehen: Bereits drei Monate vor Ablauf der Frist hat die US-Gesundheitsbehörde FDA einem von Vertex entwickelten Mukoviszidose-Medikament die Marktzulassung erteilt. Die Aktie... Mehr lesen zu: Vertex: Nächster Hoffnungsträger mit Zulassung | ||||
| 01.02. | Vertex Pharma's Latest FDA Approval Is Only The Beginning | 22 | Seeking Alpha | |
| 01.02. | XFRA SCOACH RESUMPTION OF UNDERLYING: US92532F1003 | 50 | Xetra Newsboard | |
| Alle strukturierten Produkte auf das Underlying US92532F1003 sind ab sofort wieder im Handel aufgenommen. All structured products on underlying US92532F1003 are resumed trading with iimmediate effect. Mehr lesen zu: XFRA SCOACH RESUMPTION OF UNDERLYING: US92532F1003 | ||||
| 01.02. | XFRA VX1: WIEDERAUFNAHME/RESTART | 64 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE WIRD MIT SOFORTIGER WIRKUNG WIEDER IN DEN HANDEL AUFGENOMMEN: THE FOLLOWING SHARE IS RESUMED TRADING WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN VERTEX PHARMACEUTICALS... Mehr lesen zu: XFRA VX1: WIEDERAUFNAHME/RESTART | ||||
| 31.01. | Vertex Pharmaceuticals Shares Popped: What You Need to Know | 24 | Motley Fool | |
| 31.01. | Vertex's Kalydeco Gets FDA Approval To Treat Cystic Fibrosis, Stock Up | 96 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Shares of Vertex Pharmaceuticals Inc.
(VRTX) gained 8 percent Tuesday noon, after the US Food and Drug Administration
approved Kalydeco as the first... Mehr lesen zu: Vertex's Kalydeco Gets FDA Approval To Treat Cystic Fibrosis, Stock Up | ||||
| 31.01. | Vertex Pharma Surging on FDA Approval | 18 | Benzinga.com | |
| 31.01. | Shares of Vertex Pharmaceuticals Receive a Boost, Up 6.9% | 9 | SmarTrend | |
| 31.01. | Vertex Pharma Receives FDA Approval For Kalydecotm To Treat Cystic Fibrosis | 95 | AFX News | |
| CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX)
announced Tuesday that FDA has approved Kalydecotm or ivacaftor to treat the
underlying cause of cystic fibrosis... Mehr lesen zu: Vertex Pharma Receives FDA Approval For Kalydecotm To Treat Cystic Fibrosis | ||||
| 31.01. | XFRA SCOACH SUSPENSION OF UNDERLYING: US92532F1003 | 83 | Xetra Newsboard | |
| Alle strukturierten Produkte auf das Underlying US92532F1003 sind ab sofort ausgesetzt. All structured products on underlying US92532F1003 are suspended with immediate effect. Mehr lesen zu: XFRA SCOACH SUSPENSION OF UNDERLYING: US92532F1003 | ||||
| 31.01. | XFRA VX1: AUSSETZUNG/SUSPENSION | 154 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL VERTEX PHARMACEUTICALS INC VX1 US92532F1003 BAW... Mehr lesen zu: XFRA VX1: AUSSETZUNG/SUSPENSION | ||||
| 31.01. | UPDATE: Vertex Pharmaceuticals Confirms FDA Approves KALYDECO, the First Medicine to Treat the Underlying Cause of Cystic Fibrosis | 22 | Benzinga.com | |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
